NDAORALTABLETPriority Review
Approved
Feb 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Clinical Trials (5)
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Started Feb 2026
16 enrolled
Colorectal CancerRegorafenibHigh Risk Patients
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Started Jan 2026
30 enrolled
Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
Started Oct 2025
0Rectal CancerRectal Cancer Recurrent
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Started May 2025
Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)
Started Sep 2024
104 enrolled
Meningioma, Malignant